Literature DB >> 7037873

Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

K White, G Simpson.   

Abstract

Recent studies have shown that monoamine oxidase inhibitors (MAOIs), in appropriate patients and with proper precautions, are not as dangerous as once thought, especially in comparison to alternative antidepressants. We review the literature regarding the combined use of MAOIs and tricyclic antidepressants, which has been reported to be both highly toxic and highly effective. A large number of reports of adverse effects and their management, uncontrolled clinical trials, and animal studies are summarized. We also discuss the three controlled studies of combined MAOI-tricyclic therapy that have been undertaken. We conclude that the hazards of combination therapy have been exaggerated and that MAOI-tricyclic therapy is a reasonable approach in patients found resistant to standard antidepressant treatment if certain precautions are observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7037873     DOI: 10.1097/00004714-198109000-00002

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

1.  Psychiatry-important advances in clinical medicine: combined tricyclic and monoamine-oxidase inhibitor antidepressant treatment.

Authors:  K White
Journal:  West J Med       Date:  1983-03

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

3.  Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.

Authors:  A Korn; H G Eichler; R Fischbach; S Gasic
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

Review 6.  Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.

Authors:  J C Fleishaker
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 7.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

8.  Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 9.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

10.  Drug treatment of phobias. Efficacy and optimum use.

Authors:  A P Levin; M R Liebowitz
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.